{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T10:48:12Z","timestamp":1787827692536,"version":"build-2784847793"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100006469","name":"Fundo para o Desenvolvimento das Ci\u00eancias e da Tecnologia","doi-asserted-by":"publisher","award":["0069\/2025\/AFJ"],"award-info":[{"award-number":["0069\/2025\/AFJ"]}],"id":[{"id":"10.13039\/501100006469","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-026-02856-6","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T10:17:30Z","timestamp":1775729850000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["An AI-derived peptide PCa2 suppresses pancreatic cancer growth via modulation of the ErbB\/PI3K\/AKT\/mTOR\/MYC signaling axis"],"prefix":"10.1186","volume":"24","author":[{"given":"Weimin","family":"Zuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixin","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koon Ho","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley W. I.","family":"Siu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre K.","family":"Tashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda G.","family":"Assaraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang Fai","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"issue":"1","key":"2856_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer Stat 2024 CA: Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"Cancer Stat 2024 CA: Cancer J Clin"},{"issue":"1","key":"2856_CR2","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1186\/s12885-025-14110-2","volume":"25","author":"W Liu","year":"2025","unstructured":"Liu W, et al. Global disparities in the burden of pancreatic cancer (1990\u20132021): insights from the 2021 Global Burden of Disease study. BMC Cancer. 2025;25(1):722.","journal-title":"BMC Cancer"},{"issue":"3","key":"2856_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"Cancer J Clin"},{"issue":"8","key":"2856_CR4","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1001\/jamaoncol.2024.1930","volume":"10","author":"AL Blackford","year":"2024","unstructured":"Blackford AL, et al. Pancreatic Cancer Surveillance and Survival of High-Risk Individuals. JAMA Oncol. 2024;10(8):1087\u201396.","journal-title":"JAMA Oncol"},{"issue":"10","key":"2856_CR5","first-page":"971","volume":"62","author":"J Rui","year":"2024","unstructured":"Rui J, et al. Progress in the diagnosis and treatment of pancreatic cancer with acute pancreatitis as the initial symptom. Chin J Surg. 2024;62(10):971\u20135.","journal-title":"Chin J Surg"},{"issue":"4","key":"2856_CR6","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s00535-020-01666-y","volume":"55","author":"T Okusaka","year":"2020","unstructured":"Okusaka T, Furuse J. Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines. J Gastroenterol. 2020;55(4):369\u201382.","journal-title":"J Gastroenterol"},{"issue":"3","key":"2856_CR7","doi-asserted-by":"publisher","first-page":"238","DOI":"10.21147\/j.issn.1000-9604.2022.03.05","volume":"34","author":"YP Zhao","year":"2022","unstructured":"Zhao YP, et al. National guidelines for diagnosis and treatment of pancreatic cancer 2022 in China (English version) National Health Commission of the People\u2019s Republic of China. Chin J Cancer Res. 2022;34(3):238\u2013.","journal-title":"Chin J Cancer Res"},{"issue":"8","key":"2856_CR8","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1002\/ijc.34809","volume":"154","author":"HM Bizuayehu","year":"2024","unstructured":"Bizuayehu HM, et al. Global burden of 34 cancers among women in 2020 and projections to 2040: population-based data from 185 countries\/territories. Int J Cancer. 2024;154(8):1377\u201393.","journal-title":"Int J Cancer"},{"issue":"3","key":"2856_CR9","doi-asserted-by":"publisher","first-page":"678","DOI":"10.3892\/ijo.2020.5099","volume":"57","author":"W Chiangjong","year":"2020","unstructured":"Chiangjong W, Chutipongtanate S, Hongeng S. Anticancer peptide: physicochemical property, functional aspect and trend in clinical application (review). Int J Oncol. 2020;57(3):678\u201396.","journal-title":"Int J Oncol"},{"issue":"7","key":"2856_CR10","doi-asserted-by":"publisher","first-page":"846","DOI":"10.3390\/foods9070846","volume":"9","author":"A Jakubczyk","year":"2020","unstructured":"Jakubczyk A, et al. Current trends of bioactive peptides-new sources and therapeutic effect. Foods. 2020;9(7):846.","journal-title":"Foods"},{"key":"2856_CR11","doi-asserted-by":"publisher","first-page":"114996","DOI":"10.1016\/j.biopha.2023.114996","volume":"164","author":"RK Chinnadurai","year":"2023","unstructured":"Chinnadurai RK, et al. Current research status of anti-cancer peptides: Mechanism of action, production, and clinical applications. Biomed Pharmacother. 2023;164:114996.","journal-title":"Biomed Pharmacother"},{"issue":"10","key":"2856_CR12","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1016\/j.bmc.2017.06.052","volume":"26","author":"JL Lau","year":"2018","unstructured":"Lau JL, Dunn MK. Therapeutic peptides: Historical perspectives, current development trends, and future directions. Bioorg Med Chem. 2018;26(10):2700\u20137.","journal-title":"Bioorg Med Chem"},{"issue":"4","key":"2856_CR13","doi-asserted-by":"publisher","first-page":"494","DOI":"10.2174\/1574893615999200813192148","volume":"16","author":"F Dong","year":"2021","unstructured":"Dong F, et al. The prospect of bioactive peptide research: a review on databases and tools. Curr Bioinform. 2021;16(4):494\u2013504.","journal-title":"Curr Bioinform"},{"issue":"11","key":"2856_CR14","doi-asserted-by":"publisher","first-page":"5116","DOI":"10.1021\/jacs.2c00216","volume":"144","author":"H Dong","year":"2022","unstructured":"Dong H, et al. Design and ribosomal incorporation of noncanonical disulfide-directing motifs for the development of multicyclic peptide libraries. J Am Chem Soc. 2022;144(11):5116\u201325.","journal-title":"J Am Chem Soc"},{"issue":"10","key":"2856_CR15","doi-asserted-by":"publisher","first-page":"4745","DOI":"10.1021\/ct500592m","volume":"10","author":"Y Shen","year":"2014","unstructured":"Shen Y, et al. Improved PEP-FOLD approach for peptide and miniprotein structure prediction. J Chem Theory Comput. 2014;10(10):4745\u201358.","journal-title":"J Chem Theory Comput"},{"issue":"15","key":"2856_CR16","doi-asserted-by":"publisher","first-page":"6174","DOI":"10.1021\/acs.jcim.4c00501","volume":"64","author":"H-H Cheong","year":"2024","unstructured":"Cheong H-H, et al. Identification of anticancer peptides from the genome of Candida albicans: in silico screening, in vitro and in vivo validations. J Chem Inf Model. 2024;64(15):6174\u201389.","journal-title":"J Chem Inf Model"},{"issue":"7","key":"2856_CR17","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1158\/1535-7163.MCT-19-1131","volume":"19","author":"CK Milton","year":"2020","unstructured":"Milton CK, et al. A Genome-scale CRISPR Screen Identifies the ERBB and mTOR Signaling Networks as Key Determinants of Response to PI3K Inhibition in Pancreatic Cancer. Mol Cancer Ther. 2020;19(7):1423\u201335.","journal-title":"Mol Cancer Ther"},{"key":"2856_CR18","doi-asserted-by":"publisher","first-page":"1427802","DOI":"10.3389\/fonc.2024.1427802","volume":"14","author":"M Mustafa","year":"2024","unstructured":"Mustafa M, et al. Investigating underlying molecular mechanisms, signaling pathways, emerging therapeutic approaches in pancreatic cancer. Front Oncol. 2024;14:1427802.","journal-title":"Front Oncol"},{"key":"2856_CR19","doi-asserted-by":"crossref","unstructured":"Mehra S, et al., Targeting PI3K Pathway in Pancreatic Ductal Adenocarcinoma: Rationale and Progress. Cancers (Basel). 2021;13(17):p.4434.","DOI":"10.3390\/cancers13174434"},{"issue":"2","key":"2856_CR20","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1158\/1535-7163.MCT-18-0464","volume":"18","author":"TM Totiger","year":"2019","unstructured":"Totiger TM, et al. Urolithin A, a Novel Natural Compound to Target PI3K\/AKT\/mTOR Pathway in Pancreatic Cancer. Mol Cancer Ther. 2019;18(2):301\u201311.","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"2856_CR21","doi-asserted-by":"publisher","first-page":"165","DOI":"10.21037\/atm.2016.05.11","volume":"4","author":"C Kosmidis","year":"2016","unstructured":"Kosmidis C, et al. Pancreatic cancer from bench to bedside: molecular pathways and treatment options. Ann Transl Med. 2016;4(9):165.","journal-title":"Ann Transl Med"},{"issue":"1","key":"2856_CR22","doi-asserted-by":"publisher","first-page":"5241","DOI":"10.1038\/s41598-020-62106-8","volume":"10","author":"N Meyers","year":"2020","unstructured":"Meyers N, et al. Differential impact of the ERBB receptors EGFR and ERBB2 on the initiation of precursor lesions of pancreatic ductal adenocarcinoma. Sci Rep. 2020;10(1):5241.","journal-title":"Sci Rep"},{"issue":"1","key":"2856_CR23","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13046-019-1160-9","volume":"38","author":"T Lin","year":"2019","unstructured":"Lin T, et al. Valproic acid exhibits anti-tumor activity selectively against EGFR\/ErbB2\/ErbB3-coexpressing pancreatic cancer via induction of ErbB family members-targeting microRNAs. J Experimental Clin Cancer Res. 2019;38(1):150.","journal-title":"J Experimental Clin Cancer Res"},{"issue":"18","key":"2856_CR24","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1093\/bioinformatics\/btn392","volume":"24","author":"R Gautier","year":"2008","unstructured":"Gautier R, et al. HELIQUEST: a web server to screen sequences with specific alpha-helical properties. Bioinformatics. 2008;24(18):2101\u20132.","journal-title":"Bioinformatics"},{"issue":"6","key":"2856_CR25","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s10822-005-8694-y","volume":"19","author":"IV Tetko","year":"2005","unstructured":"Tetko IV, et al. Virtual computational chemistry laboratory\u2013design and description. J Comput Aided Mol Des. 2005;19(6):453\u201363.","journal-title":"J Comput Aided Mol Des"},{"issue":"W1","key":"2856_CR26","doi-asserted-by":"publisher","first-page":"W449","DOI":"10.1093\/nar\/gkw329","volume":"44","author":"A Lamiable","year":"2016","unstructured":"Lamiable A, et al. PEP-FOLD3: faster de novo structure prediction for linear peptides in solution and in complex. Nucleic Acids Res. 2016;44(W1):W449\u201354.","journal-title":"Nucleic Acids Res"},{"issue":"Web Server issu","key":"2856_CR27","doi-asserted-by":"publisher","first-page":"W288","DOI":"10.1093\/nar\/gks419","volume":"40","author":"P Th\u00e9venet","year":"2012","unstructured":"Th\u00e9venet P, et al. PEP-FOLD: an updated de novo structure prediction server for both linear and disulfide bonded cyclic peptides. Nucleic Acids Res. 2012;40(Web Server issue):W288\u201393.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2856_CR28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41540-024-00397-7","volume":"10","author":"C Ma","year":"2024","unstructured":"Ma C, Gurkan-Cavusoglu E. A comprehensive review of computational cell cycle models in guiding cancer treatment strategies. NPJ Syst Biology Appl. 2024;10(1):71.","journal-title":"NPJ Syst Biology Appl"},{"issue":"11","key":"2856_CR29","doi-asserted-by":"publisher","first-page":"e23734","DOI":"10.1096\/fj.202400769R","volume":"38","author":"S Cavalu","year":"2024","unstructured":"Cavalu S, et al. Cell cycle machinery in oncology: a comprehensive review of therapeutic targets. FASEB J. 2024;38(11):e23734.","journal-title":"FASEB J"},{"issue":"1","key":"2856_CR30","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12860-024-00521-9","volume":"25","author":"M Arito","year":"2024","unstructured":"Arito M, et al. Role of layilin in regulating mitochondria-mediated apoptosis: a study on B cell lymphoma (BCL)-2 family proteins. BMC Mol Cell Biology. 2024;25(1):24.","journal-title":"BMC Mol Cell Biology"},{"issue":"18","key":"2856_CR31","doi-asserted-by":"publisher","first-page":"e70066","DOI":"10.1096\/fj.202400313R","volume":"38","author":"GM Fogo","year":"2024","unstructured":"Fogo GM, et al. Mitochondrial membrane potential and oxidative stress interact to regulate Oma1-dependent processing of Opa1 and mitochondrial dynamics. FASEB J. 2024;38(18):e70066.","journal-title":"FASEB J"},{"issue":"5","key":"2856_CR32","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3390\/toxins15050347","volume":"15","author":"Z Deng","year":"2023","unstructured":"Deng Z, et al. The potent antitumor activity of Smp43 against non-small-cell lung cancer A549 cells via inducing membranolysis and mitochondrial dysfunction. Toxins. 2023;15(5):347.","journal-title":"Toxins"},{"issue":"11","key":"2856_CR33","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1002\/1878-0261.13473","volume":"17","author":"K Hedegger","year":"2023","unstructured":"Hedegger K, et al. Trapping all ERBB ligands decreases pancreatic lesions in a murine model of pancreatic ductal adenocarcinoma. Mol Oncol. 2023;17(11):2415\u201331.","journal-title":"Mol Oncol"},{"issue":"4","key":"2856_CR34","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/epigenomes7040024","volume":"7","author":"G Androutsopoulos","year":"2023","unstructured":"Androutsopoulos G, et al. The ErbB signaling network and its potential role in endometrial cancer. Epigenomes. 2023;7(4):24.","journal-title":"Epigenomes"},{"key":"2856_CR35","doi-asserted-by":"publisher","first-page":"1168444","DOI":"10.3389\/fimmu.2023.1168444","volume":"14","author":"E Rabia","year":"2023","unstructured":"Rabia E, et al. Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer. Front Immunol. 2023;14:1168444.","journal-title":"Front Immunol"},{"issue":"7","key":"2856_CR36","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1093\/jimmun\/vkaf063","volume":"214","author":"G Zhou","year":"2025","unstructured":"Zhou G, et al. Enhanced antibody-mediated cellular cytotoxicity of germline-like anti-HER2 antibodies through a point mutation in complementarity-determining regions. J Immunol. 2025;214(7):1849\u201359.","journal-title":"J Immunol"},{"issue":"5","key":"2856_CR37","doi-asserted-by":"publisher","first-page":"360","DOI":"10.6004\/jnccn.2024.7050","volume":"22","author":"N Jhala","year":"2024","unstructured":"Jhala N, Petersen J, Jhala D. Molecular tests in pancreatic cancer: critical role of molecular testing, expanding access, and adherence to the NCCN guidelines for pancreatic cancer. J Natl Compr Canc Netw. 2024;22(5):360\u20132.","journal-title":"J Natl Compr Canc Netw"},{"key":"2856_CR38","doi-asserted-by":"publisher","first-page":"1115405","DOI":"10.3389\/fonc.2023.1115405","volume":"13","author":"L Schubert","year":"2023","unstructured":"Schubert L, et al. ERBB family fusions are recurrent and actionable oncogenic targets across cancer types. Front Oncol. 2023;13:1115405.","journal-title":"Front Oncol"},{"issue":"2","key":"2856_CR39","first-page":"100103","volume":"2","author":"X Du","year":"2021","unstructured":"Du X, et al. Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors. Innov (Camb). 2021;2(2):100103.","journal-title":"Innov (Camb)"},{"issue":"1","key":"2856_CR40","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ccell.2023.12.002","volume":"42","author":"G Mucciolo","year":"2024","unstructured":"Mucciolo G, et al. EGFR-activated myofibroblasts promote metastasis of pancreatic cancer. Cancer Cell. 2024;42(1):101\u201318.","journal-title":"Cancer Cell"},{"issue":"1","key":"2856_CR41","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/bph.16141","volume":"181","author":"J Kandhavelu","year":"2024","unstructured":"Kandhavelu J, et al. A novel EGFR inhibitor, HNPMI, regulates apoptosis and oncogenesis by modulating BCL-2\/BAX and p53 in colon cancer. Br J Pharmacol. 2024;181(1):107\u201324.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"2856_CR42","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1080\/15384047.2022.2054257","volume":"23","author":"D Han","year":"2022","unstructured":"Han D, et al. The NF-kappaB\/miR-488\/ERBB2 axis modulates pancreatic cancer cell malignancy and tumor growth through cell cycle signaling. Cancer Biol Ther. 2022;23(1):294\u2013309.","journal-title":"Cancer Biol Ther"},{"key":"2856_CR43","doi-asserted-by":"publisher","first-page":"1339302","DOI":"10.3389\/fonc.2024.1339302","volume":"14","author":"A Barzi","year":"2024","unstructured":"Barzi A, et al. ERBB2 (HER2) amplifications and co-occurring KRAS alterations in the circulating cell-free DNA of pancreatic ductal adenocarcinoma patients and response to HER2 inhibition. Front Oncol. 2024;14:1339302.","journal-title":"Front Oncol"},{"issue":"8","key":"2856_CR44","doi-asserted-by":"publisher","first-page":"107499","DOI":"10.1016\/j.jbc.2024.107499","volume":"300","author":"Q Kang","year":"2024","unstructured":"Kang Q, et al. ErbB3 is required for hyperaminoacidemia-induced pancreatic alpha cell hyperplasia. J Biol Chem. 2024;300(8):107499.","journal-title":"J Biol Chem"},{"issue":"7","key":"2856_CR45","doi-asserted-by":"publisher","first-page":"167316","DOI":"10.1016\/j.bbadis.2024.167316","volume":"1870","author":"Z Zhu","year":"2024","unstructured":"Zhu Z, et al. Pen2\/ErbB4 signaling regulates stemness of pancreatic ductal carcinoma. Biochim ET Biophys Acta - Mol Basis Disease. 2024;1870(7):167316.","journal-title":"Biochim ET Biophys Acta - Mol Basis Disease"},{"issue":"18","key":"2856_CR46","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1158\/0008-5472.CAN-23-1313","volume":"83","author":"KCM Gulay","year":"2023","unstructured":"Gulay KCM, et al. Dual inhibition of KRASG12D and pan-EebB Is synergistic in pancreatic ductal adenocarcinoma. Cancer Res. 2023;83(18):3001\u201312.","journal-title":"Cancer Res"},{"issue":"6","key":"2856_CR47","doi-asserted-by":"publisher","first-page":"787","DOI":"10.2174\/1389201022666210719161453","volume":"23","author":"A Sahu","year":"2022","unstructured":"Sahu A, et al. Impact of ErbB receptors and anticancer drugs against breast cancer: a review. Curr Pharm Biotechnol. 2022;23(6):787\u2013802.","journal-title":"Curr Pharm Biotechnol"},{"key":"2856_CR48","doi-asserted-by":"crossref","unstructured":"Cheong H-H, et al. Identification of Anticancer Peptides from the Genome of Candida albicans: in Silico Screening, in Vitro and in Vivo Validations. J Chem Inf Model. 2024;64(15):6174-6189.","DOI":"10.1021\/acs.jcim.4c00501"},{"key":"2856_CR49","doi-asserted-by":"crossref","unstructured":"Ariosa AR, et al. A perspective on the role of autophagy in cancer. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2021;1867(12):166262.","DOI":"10.1016\/j.bbadis.2021.166262"},{"key":"2856_CR50","doi-asserted-by":"crossref","unstructured":"Rakesh R, et al. Role and regulation of autophagy in cancer. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2022;1868(7):166400.","DOI":"10.1016\/j.bbadis.2022.166400"},{"issue":"5","key":"2856_CR51","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00418-008-0401-3","volume":"129","author":"K Roepstorff","year":"2008","unstructured":"Roepstorff K, et al. Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer. Histochem Cell Biol. 2008;129(5):563\u201378.","journal-title":"Histochem Cell Biol"},{"issue":"13","key":"2856_CR52","doi-asserted-by":"publisher","first-page":"ar134","DOI":"10.1091\/mbc.E23-02-0058","volume":"34","author":"I Pinilla-Macua","year":"2023","unstructured":"Pinilla-Macua I, Sorkin A. Cbl and Cbl-b independently regulate EGFR through distinct receptor interaction modes. Mol Biol Cell. 2023;34(13):ar134.","journal-title":"Mol Biol Cell"},{"issue":"6","key":"2856_CR53","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.molcel.2006.02.018","volume":"21","author":"F Huang","year":"2006","unstructured":"Huang F, et al. Differential regulation of EGF receptor internalization and degradation by multiubiquitination within the kinase domain. Mol Cell. 2006;21(6):737\u201348.","journal-title":"Mol Cell"},{"key":"2856_CR54","doi-asserted-by":"crossref","unstructured":"Hua F, et al. Linear Ubiquitination Mediates EGFR-Induced NF-kappaB Pathway and Tumor Development. Int J Mol Sci. 2021;22(21):11875.","DOI":"10.3390\/ijms222111875"},{"issue":"5","key":"2856_CR55","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.cellsig.2009.01.028","volume":"21","author":"SM Jansen","year":"2009","unstructured":"Jansen SM, et al. ErbB2 and ErbB4 Cbl binding sites can functionally replace the ErbB1 Cbl binding site. Cell Signal. 2009;21(5):810\u20138.","journal-title":"Cell Signal"},{"issue":"23","key":"2856_CR56","doi-asserted-by":"publisher","first-page":"14843","DOI":"10.1073\/pnas.232580999","volume":"99","author":"XB Qiu","year":"2002","unstructured":"Qiu XB, Goldberg AL. Nrdp1\/FLRF is a ubiquitin ligase promoting ubiquitination and degradation of the epidermal growth factor receptor family member, ErbB3. Proc Natl Acad Sci U S A. 2002;99(23):14843\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"2856_CR57","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1016\/j.bbamcr.2017.08.011","volume":"1864","author":"AM Fosdahl","year":"2017","unstructured":"Fosdahl AM, et al. ErbB3 interacts with Hrs and is sorted to lysosomes for degradation. Biochim Biophys Acta Mol Cell Res. 2017;1864(12):2241\u201352.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"issue":"9","key":"2856_CR58","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.semcdb.2010.09.006","volume":"21","author":"KL Carraway","year":"2010","unstructured":"Carraway KL 3rd. E3 ubiquitin ligases in ErbB receptor quantity control. Semin Cell Dev Biol. 2010;21(9):936\u201343.","journal-title":"Semin Cell Dev Biol"},{"issue":"6","key":"2856_CR59","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1128\/MCB.01245-06","volume":"27","author":"Z Cao","year":"2007","unstructured":"Cao Z, et al. Neuregulin-induced ErbB3 downregulation is mediated by a protein stability cascade involving the E3 ubiquitin ligase Nrdp1. Mol Cell Biol. 2007;27(6):2180\u20138.","journal-title":"Mol Cell Biol"},{"issue":"2","key":"2856_CR60","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/sj.bjc.6601500","volume":"90","author":"C Sweeney","year":"2004","unstructured":"Sweeney C, Carraway KL 3rd. Negative regulation of ErbB family receptor tyrosine kinases. Br J Cancer. 2004;90(2):289\u201393.","journal-title":"Br J Cancer"},{"issue":"18","key":"2856_CR61","doi-asserted-by":"publisher","first-page":"8716","DOI":"10.1158\/0008-5472.CAN-06-3731","volume":"67","author":"X Li","year":"2007","unstructured":"Li X, et al. Degradation of HER2 by Cbl-based chimeric ubiquitin ligases. Cancer Res. 2007;67(18):8716\u201324.","journal-title":"Cancer Res"},{"key":"2856_CR62","doi-asserted-by":"crossref","unstructured":"Ebadi P, Stratton CM, Olsen SK. E3 ubiquitin ligases in signaling, disease, and therapeutics. Trends Biochem Sci. 2025;50(11):960-976.","DOI":"10.1016\/j.tibs.2025.07.009"},{"key":"2856_CR63","doi-asserted-by":"publisher","first-page":"1432545","DOI":"10.3389\/fphar.2024.1432545","volume":"15","author":"J Ren","year":"2024","unstructured":"Ren J, et al. The role of CBL family ubiquitin ligases in cancer progression and therapeutic strategies. Front Pharmacol. 2024;15:1432545.","journal-title":"Front Pharmacol"},{"issue":"30","key":"2856_CR64","doi-asserted-by":"publisher","first-page":"20993","DOI":"10.18632\/oncotarget.24772","volume":"9","author":"S Engelberg","year":"2018","unstructured":"Engelberg S, et al. Cancer cell-selective, clathrin-mediated endocytosis of aptamer decorated nanoparticles. Oncotarget. 2018;9(30):20993\u20131006.","journal-title":"Oncotarget"},{"issue":"10","key":"2856_CR65","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/s41419-019-1870-0","volume":"10","author":"S Engelberg","year":"2019","unstructured":"Engelberg S, et al. Selective eradication of human non-small cell lung cancer cells using aptamer-decorated nanoparticles harboring a cytotoxic drug cargo. Cell Death Dis. 2019;10(10):702.","journal-title":"Cell Death Dis"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-026-02856-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02856-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02856-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T04:51:30Z","timestamp":1779943890000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12964-026-02856-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2856"],"URL":"https:\/\/doi.org\/10.1186\/s12964-026-02856-6","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"13 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved by the Animal Research Ethics Committee of the University of Macau (Approval No.: UMARE-006\u20132024).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"315"}}